Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and Treg cells
The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
Although immune mechanisms can suppress tumour growth, tumours establish potent, overlapping mechanisms that mediate immune evasion. Emerging evidence suggests a link between angiogenesis and the tolerance of tumours to immune mechanisms. Hypoxia, a condition that is known to drive angiogenesis in tumours, results in the release of damage-associated pattern molecules, which can trigger the rejection of tumours by the immune system. Thus, the counter-activation of tolerance mechanisms at the site of tumour hypoxia would be a crucial condition for maintaining the immunological escape of tumours. However, a direct link between tumour hypoxia and tolerance through the recruitment of regulatory cells has not been established. We proposed that tumour hypoxia induces the expression of chemotactic factors that promote tolerance. Here we show that tumour hypoxia promotes the recruitment of regulatory T (T(reg)) cells through induction of expression of the chemokine CC-chemokine ligand 28 (CCL28), which, in turn, promotes tumour tolerance and angiogenesis. Thus, peripheral immune tolerance and angiogenesis programs are closely connected and cooperate to sustain tumour growth.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Hypoxia, through HIF-1α, drives the conversion of MDSCs into antigen-nonspecific suppressors of T cell function and promotes the differentiation of MDSCs into immune-suppressive TAMs, further potentiating the immune-suppressive network [80].”
From Revisiting the HIF switch in the tumor and its immune microenvironment. (2022) · cites this paper as [80]
In the citing paper
“For example, both HIF-1α and HIF-2α induce the production of CCL28, which promotes the recruitment of MDSCs into hepatocellular tumors, whereas HIF-1α induces production of CCL26 that enhances recruitment of Tregs into ovarian tumors (Table 1) [69, 70].”
From The HIF Axes in Cancer - Angiogenesis, Metabolism and Immune-Modulation (2025) · cites this paper as [69]
In the citing paper
“For example, both HIF-1α and HIF-2α induce the production of CCL28, which promotes the recruitment of MDSCs into hepatocellular tumors, whereas HIF-1α induces production of CCL26 that enhances recruitment of Tregs into ovarian tumors (Table 1) [69, 70].”
From The HIF Axes in Cancer - Angiogenesis, Metabolism and Immune-Modulation (2025) · cites this paper as [69]
In the citing paper
“In addition to increasing drug resistance, a high SS could influence tumor cells' gene expression, comprise immune cells ability to kill cancerous cells or even turn macrophages to tumorfriendly cells, thereby enhancing the metastatic potential of cancer cells [180-184].”
From Microfluidic modelling of the tumor microenvironment for anti-cancer drug development (2019) · cites this paper as [181]
In the citing paper
“tumours secrete soluble factors, such as C-C-motif chemokine ligand 2 (CCL2), CCL28, C-X-C-motif chemokine ligand 8 (CXCL8), CXCL12, ANG2, VEGF, PlGF, and adenosine, all of which promote the recruitment of immunosuppressive cells7,17–20 (FIG. 2)”
From Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges (2018) · cites this paper as [17]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Curiel, T. J., Coukos, G., Zou, L., Alvarez, X., Cheng, P., Mottram, P., Evdemon-Hogan, M., Conejo-Garcia, J. R., Zhang, L., Burow, M., et al. (2004) · Nature Medicine · doi:10.1038/nm1093 · Cited by 5,151
Self-citationSummaries of Affymetrix GeneChip probe level data
Irizarry, R. A. (2003) · Nucleic Acids Research · doi:10.1093/nar/gng015 · Cited by 4,887
Camp, R. L., Dolled-Filhart, M., & Rimm, D. L. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0713 · Cited by 3,744
Intratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian Cancer
Zhang, L., Conejo-Garcia, J. R., Katsaros, D., Gimotty, P. A., Massobrio, M., Regnani, G., Makrigiannakis, A., Gray, H., Schlienger, K., Liebman, M. N., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020177 · Cited by 3,397
Self-citationImmunosuppressive networks in the tumour environment and their therapeutic relevance
Zou, W. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1586 · Cited by 2,057
Oncogenic pathway signatures in human cancers as a guide to targeted therapies
Bild, A. H., Yao, G., Chang, J. T., Wang, Q., Potti, A., Chasse, D., Joshi, M.-B., Harpole, D., Lancaster, J. M., Berchuck, A., et al. (2006) · Nature · doi:10.1038/nature04296 · Cited by 2,032
Gabrilovich, D. I., Chen, H. L., Girgis, K. R., Cunningham, H. T., Meny, G. M., Nadaf, S., Kavanaugh, D., & Carbone, D. P. (1996) · Nature Medicine · doi:10.1038/nm1096-1096 · Cited by 1,977
Novel Molecular Subtypes of Serous and Endometrioid Ovarian Cancer Linked to Clinical Outcome
Tothill, R. W., Tinker, A. V., George, J., Brown, R., Fox, S. B., Lade, S., Johnson, D. S., Trivett, M. K., Etemadmoghadam, D., Locandro, B., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0196 · Cited by 1,467
Adaptive immunity maintains occult cancer in an equilibrium state
Koebel, C. M., Vermi, W., Swann, J. B., Zerafa, N., Rodig, S. J., Old, L. J., Smyth, M. J., & Schreiber, R. D. (2007) · Nature · doi:10.1038/nature06309 · Cited by 1,436
Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity
Curiel, T. J., Wei, S., Dong, H., Alvarez, X., Cheng, P., Mottram, P., Krzysiek, R., Knutson, K. L., Daniel, B., Zimmermann, M. C., et al. (2003) · Nature Medicine · doi:10.1038/nm863 · Cited by 1,314
Cited by
Items 201–300 of 1,002
Huo, D., Liu, S., Zhang, C., He, J., Zhou, Z., Zhang, H., & Hu, Y. (2017) · ACS Nano · doi:10.1021/acsnano.7b04737 · Cited by 172
Connecting blood and intratumoral Treg cell activity in predicting future relapse in breast cancer
Wang, L., Simons, D. L., Lu, X., Tu, T. Y., Solomon, S., Wang, R., Rosario, A., Avalos, C., Schmolze, D., Yim, J., et al. (2019) · Nature Immunology · doi:10.1038/s41590-019-0429-7 · Cited by 174
Self-citationMechanisms of Fetal T Cell Tolerance and Immune Regulation
Rackaityte, E., & Halkias, J. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00588 · Cited by 171
PD-1 and PD-L1 inhibitors in cold colorectal cancer: challenges and strategies
Lin, K. X., Istl, A. C., Quan, D., Skaro, A. I., Tang, E. S.-T., & Zheng, X. (2023) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-023-03520-5 · Cited by 179
Cancer Stem Cells and Their Microenvironment: Biology and Therapeutic Implications
Lau, E. Y.-T., Ho, N. P.-Y., & Lee, T. K.-W. (2017) · Stem Cells International · doi:10.1155/2017/3714190 · Cited by 167
Biomimetic Delivery with Micro‐ and Nanoparticles
Balmert, S. C., & Little, S. R. (2012) · Advanced Materials · doi:10.1002/adma.201200224 · Cited by 167
Gropper, Y., Feferman, T., Shalit, T., Salame, T.-M., Porat, Z., & Shakhar, G. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.08.071 · Cited by 166
Ways to Enhance Lymphocyte Trafficking into Tumors and Fitness of Tumor Infiltrating Lymphocytes
Bellone, M., & Calcinotto, A. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00231 · Cited by 167
“More recently it has been reported that hypoxia within the tumor microenvironment promotes Treg recruitment through the induction of CC-chemokine ligand 28 (97).”
BackgroundDavis, R. J., Van Waes, C., & Allen, C. T. (2016) · Oral Oncology · doi:10.1016/j.oraloncology.2016.05.002 · Cited by 163
“Additional signals implicated in Treg recruitment to the TME include CCL28-CCL28R and CXCL10-CXCR3 interactions [100,101].”
BackgroundDual role of inflammatory mediators in cancer
Shrihari, T. (2017) · ecancermedicalscience · doi:10.3332/ecancer.2017.721 · Cited by 164
The Solid Mechanics of Cancer and Strategies for Improved Therapy
Stylianopoulos, T. (2017) · Journal of Biomechanical Engineering · doi:10.1115/1.4034991 · Cited by 169
“Hypoxia fuels tumor progression and treatment resistance in multiple ways [16]: it might (a) cause inflammation and immunosuppression by reducing the activity of immune cells [17,18], (b) induce a cancer stem cell-like phenotype making cancer cells more resistant to hypoxic conditions and cytotoxic drugs to drive sele…”
BackgroundKumagai, S., Itahashi, K., & Nishikawa, H. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00870-6 · Cited by 186
Liu, D., Song, L., Wei, J., Courtney, A. N., Gao, X., Marinova, E., Guo, L., Heczey, A., Asgharzadeh, S., Kim, E., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci59535 · Cited by 164
“The areas of hypoxia in both primary and metastatic sites were visualized using intravital injection of EF5 followed by staining with anti-EF5 fluorochrom-conjugated mAb (31).”
Philip, B., Ito, K., Moreno-Sanchez, R., & Ralph, S. J. (2013) · Carcinogenesis · doi:10.1093/carcin/bgt209 · Cited by 161
“Thus, hypoxia-exposed tumour cells produce greater levels of the CC-chemokine ligand 28, which selectively attracts and recruits regulatory T (Treg) cells into the tumour stroma, negatively regulating antitumour immune cell responses (105).”
Immune suppression and reversal of the suppressive tumor microenvironment
Shimizu, K., Iyoda, T., Okada, M., Yamasaki, S., & Fujii, S.-I. (2018) · International Immunology · doi:10.1093/intimm/dxy042 · Cited by 157
Immuno-Metabolism and Microenvironment in Cancer: Key Players for Immunotherapy
Giannone, G., Ghisoni, E., Genta, S., Scotto, G., Tuninetti, V., Turinetto, M., & Valabrega, G. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21124414 · Cited by 159
Natural killer cells and regulatory T cells in early pregnancy loss
Sharma, S. (2014) · The International Journal of Developmental Biology · doi:10.1387/ijdb.140109ss · Cited by 169
“It has been shown that tumor hypoxia promotes recruitment of Tregs which in turn promote immune tolerance and angiogenesis (Facciabene et al., 2011; Deng et al., 2013).”
BackgroundChemokines and Chemokine Receptors: Orchestrating Tumor Metastasization
Marcuzzi, E., Angioni, R., Molon, B., & Calì, B. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms20010096 · Cited by 173
Brueckl, W. M., Ficker, J. H., & Zeitler, G. (2020) · BMC Cancer · doi:10.1186/s12885-020-07690-8 · Cited by 158
“HCC is associated with hypoxic tumor conditions, high VEGF expression and increased angiogenesis, which can contribute to the induction of immunosuppressive cells like regulatory T cells and the promotion of immune tolerance in the tumor microenvironment (TME) [36, 97, 98].”
BackgroundInfluentialYang, L., & Lin, P. C. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.08.001 · Cited by 155
Role of Radiation Therapy in Modulation of the Tumor Stroma and Microenvironment
Menon, H., Ramapriyan, R., Cushman, T. R., Verma, V., Kim, H. H., Schoenhals, J. E., Atalar, S. C., Selek, U., Chun, S. G., Chang, J. Y., et al. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00193 · Cited by 171
“CCL28 is produced as a result of tumor hypoxia and the release of damage-associated pattern molecules (14).”
BackgroundLow-Dose Anti-Angiogenic Therapy Sensitizes Breast Cancer to PD-1 Blockade
Li, Q., Wang, Y., Jia, W., Deng, H., Li, G., Deng, W., Chen, J., Kim, B. Y. S., Jiang, W., Liu, Q., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2179 · Cited by 152
“The hypoxic tumor microenvironment also stimulates the secretion of several immunosuppressive cytokines (8) and promotes the upregulation of PD-1 on T cells (9, 10).”
BackgroundCancer immunoediting and immune dysregulation in multiple myeloma
Nakamura, K., Smyth, M. J., & Martinet, L. (2020) · Blood · doi:10.1182/blood.2020006540 · Cited by 158
Shen, J., Rees, T. W., Ji, L., & Chao, H. (2021) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2021.214016 · Cited by 159
Rickard, B. P., Conrad, C., Sorrin, A. J., Ruhi, M. K., Reader, J. C., Huang, S. A., Franco, W., Scarcelli, G., Polacheck, W. J., Roque, D. M., et al. (2021) · Cancers · doi:10.3390/cancers13174318 · Cited by 185
Chheda, Z. S., Sharma, R. K., Jala, V. R., Luster, A. D., & Haribabu, B. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1502376 · Cited by 157
“CCR5 [97], CCR10 [98] and CXCR3 [99] are some of the other chemokine receptors shown to be involved in”
Rationally Combining Anti-VEGF Therapy with Checkpoint Inhibitors in Hepatocellular Carcinoma
Hato, T., Zhu, A. X., & Duda, D. G. (2016) · Immunotherapy · doi:10.2217/imt.15.126 · Cited by 161
Immune Response Regulation in the Tumor Microenvironment by Hypoxia
Labiano, S., Palazón, A., & Melero, I. (2015) · Seminars in Oncology · doi:10.1053/j.seminoncol.2015.02.009 · Cited by 169
McDonald, P. C., Chafe, S. C., & Dedhar, S. (2016) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2016.00027 · Cited by 152
“It has also been shown that Treg are important for the formation of new blood vessels in the tumor (Facciabene et al., 2011).”
BackgroundEndothelial cells in tumor microenvironment: insights and perspectives
Leone, P., Malerba, E., Susca, N., Favoino, E., Perosa, F., Brunori, G., Prete, M., & Racanelli, V. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1367875 · Cited by 167
Hypoxia-induced CCL28 promotes recruitment of regulatory T cells and tumor growth in liver cancer
Ren, L., Yu, Y., Wang, L., Zhu, Z., Lu, R., & Yao, Z. (2016) · Oncotarget · doi:10.18632/oncotarget.12409 · Cited by 149
“Although similar mechanism has been suggested in ovarian cancer [11], it has remained to be demonstrated in liver cancer.”
BackgroundSelf-citationLança, T., & Silva-Santos, B. (2012) · OncoImmunology · doi:10.4161/onci.20068 · Cited by 149
The Tumor Microenvironment: A Pitch for Multiple Players
Schiavoni, G., Gabriele, L., & Mattei, F. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00090 · Cited by 147
“This elicits vascularization extent and thus facilitates angiogenesis itself, which in turn allow CSC proliferation and maintenance inside the cancer microenvironment (Facciabene et al., 2011; Yu et al., 2012).”
BackgroundCancer Immunotherapy: Beyond Checkpoint Blockade
Dougan, M. L., Dranoff, G., & Dougan, S. K. (2018) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030518-055552 · Cited by 164
“…circumstances is difficult for immune cells to traffic through, and VEGF also has direct immunosuppressive roles, promoting the formation of Tregs and immunosuppressive myeloid cells (Facciabene et al. 2011, Gabrilovich et al. 1998, Ghiringhelli et al. 2005, Huang et al. 2007, Terme et al. 2013).”
BackgroundHou, A., Hou, K., Huang, Q., Lei, Y., & Chen, W. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00783 · Cited by 145
“Similarly, Tregs and TAMs are recruited to and retain inside hypoxic niche by expression of CCL28 and Sema3A/Nrp1 signaling respectively (97, 98).”
BackgroundG Protein‐Coupled receptors and heterotrimeric G proteins as cancer drivers
Arang, N., & Gutkind, J. S. (2020) · FEBS Letters · doi:10.1002/1873-3468.14017 · Cited by 157
Chemokines and cancer: new immune checkpoints for cancer therapy
Karin, N. (2018) · Current Opinion in Immunology · doi:10.1016/j.coi.2018.03.004 · Cited by 158
Li, Y., Liu, Y., Wang, C., Xia, W., Zheng, J., Yang, J. W., Liu, B., Liu, J., & Liu, L. (2018) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2018.07.009 · Cited by 159
Tumor Neovascularization and Developments in Therapeutics
Katayama, Y., Uchino, J., Chihara, Y., Tamiya, N., Kaneko, Y., Yamada, T., & Takayama, K. (2019) · Cancers · doi:10.3390/cancers11030316 · Cited by 143
Strategies based on metal-based nanoparticles for hypoxic-tumor radiotherapy
Zhang, C., Yan, L., Gu, Z., & Zhao, Y. (2019) · Chemical Science · doi:10.1039/c9sc02107h · Cited by 144
Baxevanis, C. N., Fortis, S. P., & Perez, S. A. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.12.018 · Cited by 172
Hypoxia inducible factor (HIF) in the tumor microenvironment: friend or foe?
Huang, Y., Lin, D., & Taniguchi, C. M. (2017) · Science China Life Sciences · doi:10.1007/s11427-017-9178-y · Cited by 142
Colon cancer stem cells: Potential target for the treatment of colorectal cancer
Gupta, R., Bhatt, L. K., Johnston, T. P., & Prabhavalkar, K. S. (2019) · Cancer Biology & Therapy · doi:10.1080/15384047.2019.1599660 · Cited by 158
Noman, M. Z., Janji, B., Hu, S., Wu, J. C., Martelli, F., Bronte, V., & Chouaib, S. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-0405 · Cited by 143
“Similarly, hypoxia promoted the recruitment of the immunosuppressive Tregs through the induction of CCL28 expression by hypoxic tumor cells (6).”
BackgroundImmune regulation of metastasis: mechanistic insights and therapeutic opportunities
Blomberg, O. S., Spagnuolo, L., & de Visser, K. E. (2018) · Disease Models & Mechanisms · doi:10.1242/dmm.036236 · Cited by 148
“Other tumor-infiltrating immune cells, such as Tregs and mast cells, can also produce VEGFA (Facciabene et al., 2011; Takanami et al., 2000).”
BackgroundLiu, L., Bai, H., Wang, C., Seery, S., Wang, Z., Duan, J., Li, S., Xue, P., Wang, G., Sun, Y., et al. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.03.016 · Cited by 149
Redefining macrophage and neutrophil biology in the metastatic cascade
Güç, E., & Pollard, J. W. (2021) · Immunity · doi:10.1016/j.immuni.2021.03.022 · Cited by 140
Treg Cells, Life History, and Diversity
Benoist, C. O., & Mathis, D. J. (2012) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a007021 · Cited by 171
Tumor Microenvironment: A New Treatment Target for Cancer
Tsai, M.-J., Chang, W.-A., Huang, M.-S., & Kuo, P.-L. (2014) · ISRN Biochemistry · doi:10.1155/2014/351959 · Cited by 139
“CCL28 derived from tumor cells has also been shown to promote the recruitment of Tregs and thereby promote tolerance of tumor and angiogenesis [36].”
Rodriguez, G., Galpin, K., McCloskey, C., & Vanderhyden, B. (2018) · Cancers · doi:10.3390/cancers10080242 · Cited by 140
Tanchot, C., Terme, M., Pere, H., Tran, T., Benhamouda, N., Strioga, M., Banissi, C., Galluzzi, L., Kroemer, G., & Tartour, E. (2013) · Cancer Microenvironment · doi:10.1007/s12307-012-0122-y · Cited by 138
“Intratumoral Tregs secrete high levels of VEGF, suggesting that they may directly contribute to angiogenesis and tumor growth [65, 70].”
BackgroundKouidhi, S., Elgaaied, A. B., & Chouaib, S. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00270 · Cited by 138
“This metabolic adaptation is mainly orchestrated through the upregulation of the transcription factor, HIF-1α.”
BackgroundInfluentialmiR-25/93 mediates hypoxia-induced immunosuppression by repressing cGAS
Wu, M.-Z., Cheng, W.-C., Chen, S.-F., Nieh, S., O’Connor, C., Liu, C.-L., Tsai, W.-W., Wu, C.-J., Martin, L., Lin, Y.-S., et al. (2017) · Nature Cell Biology · doi:10.1038/ncb3615 · Cited by 138
“For example, immunosuppressive cells (e.g., regulatory T cells) accumulate within hypoxic regions of tumors where they promote tumor progression 6–9 and activate immune tolerance mechanisms that enable cancer cells to evade host immunosurveillance.”
The opposing roles of CD 4+ T cells in anti‐tumour immunity
Ahrends, T., & Borst, J. (2018) · Immunology · doi:10.1111/imm.12941 · Cited by 140
Cancer metabolism and tumor microenvironment: fostering each other?
Yuan, Y., Li, H., Wang, P., Chen, L., Guo, D. S., Jiang, H., He, B., Qin, S., Wang, K., Li, N., et al. (2021) · Science China Life Sciences · doi:10.1007/s11427-021-1999-2 · Cited by 144
“Interestingly, tumor hypoxia promoted CCR10 Tregs recruitment by inducing chemokine CC chemokine ligand 28 (CCL28) expression in tumor cells (Facciabene et al., 2011).”
BackgroundHossain, M. A., Liu, G., Dai, B., Si, Y., Yang, Q., Wazir, J., Birnbaumer, L., & Yang, Y. (2020) · Medicinal Research Reviews · doi:10.1002/med.21727 · Cited by 154
“In addition, lack of oxygen favors the angiogenesis, vasculogenesis, as well as resistance to apoptosis and therapy.(86,87) In addition, hypoxia downregulates the expression of MHC‐I molecules on tumor cells and decreases their immunogenicity.”
BackgroundHallmarks of cancer: of all cancer cells, all the time?
Floor, S. L., Dumont, J. E., Maenhaut, C., & Raspé, E. (2012) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2012.06.005 · Cited by 187
Cellular and molecular mechanisms in cancer immune escape: a comprehensive review
Bhatia, A., & Kumar, Y. (2014) · Expert Review of Clinical Immunology · doi:10.1586/1744666x.2014.865519 · Cited by 131
Cytokine and Chemokine Signals of T‐Cell Exclusion in Tumors
Zhang, Y., Guan, X.-Y., & Jiang, P. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.594609 · Cited by 133
Khaliq, A. M., Rajamohan, M., Saeed, O. A. M., Mansouri, K., Adil, A., Zhang, C., Turk, A. A., Carstens, J. L., House, M. G., Hayat, S., et al. (2024) · Nature Genetics · doi:10.1038/s41588-024-01914-4 · Cited by 161
Colorectal cancer and immunity: What we know and perspectives
Pernot, S. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i14.3738 · Cited by 131
The dark side of tumor-associated endothelial cells
Sanctis, F. D., Ugel, S., Facciponte, J. G., & Facciabene, A. (2018) · Seminars in Immunology · doi:10.1016/j.smim.2018.02.002 · Cited by 144
“For example, hypoxia-driven secretion of CCL28 promotes T-reg recruitment [50], while CX3CL1 (fractalkine) increases T cell homing to tumors [186], and these chemokines are considered negative and positive prognostic factors, respectively.”
BackgroundSelf-citationUnraveling tumor microenvironment of small-cell lung cancer: Implications for immunotherapy
Li, T. X., & Qiao, T. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.09.005 · Cited by 142
Nuñez-Cruz, S., Gimotty, P. A., Guerra, M. W., Connolly, D. C., Wu, Y., DeAngelis, R. A., Lambris, J. D., Coukos, G., & Scholler, N. (2012) · Neoplasia · doi:10.1593/neo.121262 · Cited by 142
“Matrigel plugs were excised and digested with 1 mg/ml collagenase II and 10,000 U/ml DNAse I (Sigma) for 30 minutes at room temperature, as described [52], then resuspended in PBS and analyzed by flow cytometry for the expression of CD31 and CD144.”
BackgroundMethodSelf-citationGriesmann, H., Drexel, C., Milosevic, N., Sipos, B., Rosendahl, J., Gress, T. M., & Michl, P. (2017) · Gut · doi:10.1136/gutjnl-2015-310049 · Cited by 129
Collagen Remodeling in the Hypoxic Tumor-Mesothelial Niche Promotes Ovarian Cancer Metastasis
Natarajan, S., Foreman, K. M., Soriano, M. I., Rossen, N. S., Shehade, H., Fregoso, D. R., Eggold, J. T., Krishnan, V., Dorigo, O., Krieg, A. J., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-2616 · Cited by 129
Nanoparticles-mediated reoxygenation strategy relieves tumor hypoxia for enhanced cancer therapy
Wang, H., Li, J., Wang, Y., Gong, X., Xu, X., Wang, J., Li, Y., Sha, X., & Zhang, Z. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.12.028 · Cited by 131
Specialized immune responses in the peritoneal cavity and omentum
Liu, M., Silva-Sánchez, A., Randall, T. D., & Meza‐Perez, S. (2020) · Journal of Leukocyte Biology · doi:10.1002/jlb.5mir0720-271rr · Cited by 147
Fu, Z., Mowday, A. M., Smaill, J. B., Hermans, I. F., & Patterson, A. V. (2021) · Cells · doi:10.3390/cells10051006 · Cited by 147
“Similarly, hypoxia-induced recruitment of Tregs has been associated with a poor prognosis for patients with hepatocellular carcinoma (HCC) and basal-like breast cancer [85,93,94].”
BackgroundInfluentialRegulatory T cells in the tumour microenvironment
Imianowski, C. J., Chen, Q., Workman, C. J., & Vignali, D. A. A. (2025) · Nature reviews. Cancer · doi:10.1038/s41568-025-00832-9 · Cited by 159
Wei, F., Wang, D., Wei, J., Tang, N., Tang, L. M., Xiong, F., Guo, C. J., Zhou, M., Li, X., Li, G., et al. (2020) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-020-03581-0 · Cited by 148
Chen, J., Xu, C., Yang, K., Gao, R., Cao, Y., Liang, L., Chen, S., Xu, S., Rong, R., Wang, J., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-36747-y · Cited by 141
Hypoxia-inducible factors in cancer stem cells and inflammation
Peng, G., & Liu, Y. (2015) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2015.03.003 · Cited by 123
“Tregs may be enriched in cancer tissue by HIF-1α-dependent production of chemokines, such as CCL-28 [85].”
The immune network in thyroid cancer
Galdiero, M. R., Varricchi, G., & Marone, G. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1168556 · Cited by 131
“55 Tumor-associated DCs release VEGF-A, CXCL8/IL-8 and osteopontin.56 Human eosinophils promote angiogenesis 57 and eosinophilia can be observed in ATC patients.58 Tregs play a role in maintaining tolerance in TC and drive tumor angiogenesis through the release of VEGF-A.59 MDSCs promote tumor angiogenesis through the…”
BackgroundVoutouri, C., Polydorou, C., Papageorgis, P., Gkretsi, V., & Stylianopoulos, T. (2016) · Neoplasia · doi:10.1016/j.neo.2016.10.001 · Cited by 139
CCL28 chemokine: An anchoring point bridging innate and adaptive immunity
Mohan, T., Deng, L., & Wang, B. (2017) · International Immunopharmacology · doi:10.1016/j.intimp.2017.08.012 · Cited by 130
“[42, [75] [76] [77] Atopic asthma”
Galectin-1 as a potent target for cancer therapy: role in the tumor microenvironment
Ito, K., Stannard, K. A., Gabutero, E., Clark, A. M., Neo, S., Onturk, S., Blanchard, H., & Ralph, S. J. (2012) · Cancer and Metastasis Reviews · doi:10.1007/s10555-012-9388-2 · Cited by 148
“Furthermore, hypoxia-exposed tumor cells produce greater levels of the CC-chemokine ligand 28 (CCL28), which selectively attracts and recruits the Treg cells into the tumor stroma [80].”
BackgroundJi, L., Qian, W., Gui, L., Ji, Z., Yin, P., Lin, G. N., Wang, Y., Ma, B., & Gao, W. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-3074 · Cited by 136
“It has been shown that CCL28 mediates Treg cell migration (40, 41).”
BackgroundCancer Stem Cells: Emerging Key Players in Immune Evasion of Cancers
Lei, M. M. L., & Lee, T. K. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.692940 · Cited by 130
“Under hypoxic conditions, Tregs, which are an important source of VEGF expression, release TGF-β and indirectly regulate CSC expansion by mediating angiogenesis (Facciabene et al., 2011).”
BackgroundBile salt hydrolase in non-enterotoxigenic Bacteroides potentiates colorectal cancer
Sun, L., Zhang, Y., Cai, J., Rimal, B., Rocha, E. R., Coleman, J. P., Zhang, C., Nichols, R. G., Luo, Y., Kim, B., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-36089-9 · Cited by 140
Gupta, H. B., Clark, C. A., Yuan, B., Sareddy, G., Pandeswara, S., Padron, A. S., Hurez, V., Conejo-Garcia, J., Vadlamudi, R., Li, R., et al. (2016) · Signal Transduction and Targeted Therapy · doi:10.1038/sigtrans.2016.30 · Cited by 122
Mechanisms of Apoptosis Resistance to NK Cell-Mediated Cytotoxicity in Cancer
Sordo-Bahamonde, C., Lorenzo-Herrero, S., Payer, Á. R., Gonzalez, S., & López-Soto, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21103726 · Cited by 123
Recruitment and Expansion of Tregs Cells in the Tumor Environment—How to Target Them?
Cinier, J., Hubert, M., Besson, L., Roio, A. D., Rodriguez, C., Lombardi, V., Caux, C., & Ménétrier‐Caux, C. (2021) · Cancers · doi:10.3390/cancers13081850 · Cited by 134
“In contrast, in human ovarian and liver tumors, hypoxia favors the production of high CCL28 levels by tumor cells (Figure 1) that are correlated with poor patient survival [130] and with the recruitment of CCR10-expressing Tregs in the TME [130,131].”
BackgroundMukaida, N., Sasaki, S., & Baba, T. (2014) · Mediators of Inflammation · doi:10.1155/2014/170381 · Cited by 136
“CCL28 promotes angiogenesis and recruits Treg cells, thereby also propagating immune tolerance [18] (Figure 2).”
BackgroundDeng, B., Zhu, J.-M., Wang, Y., Liu, T.-T., Ding, Y.-B., Xiao, W.-M., Lu, G.-T., Bo, P., & Shen, X.-Z. (2013) · PLoS ONE · doi:10.1371/journal.pone.0063777 · Cited by 121
“Recently, a confirmed link between tumor hypoxia and immune tolerance through the recruitment of regulatory T cells (Tregs) has been established in ovarian cancer [9].”
BackgroundNanomedicines modulating tumor immunosuppressive cells to enhance cancer immunotherapy
Zhu, Y., Yu, X., Thamphiwatana, S., Zheng, Y., & Pang, Z. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.08.010 · Cited by 118
Overcoming cold tumors: a combination strategy of immune checkpoint inhibitors
Ouyang, P., Wang, L., Wu, J., Tian, Y., Chen, C., Li, D., Yao, Z., Chen, R., Xiang, G., Gong, J., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1344272 · Cited by 137
Self-citationCCR10 and its ligands in regulation of epithelial immunity and diseases
Xiong, N., Fu, Y., Hu, S., Xia, M., & Yang, J. (2012) · Protein & Cell · doi:10.1007/s13238-012-2927-3 · Cited by 115
“On the other hand, ovarian cancer cells under hypoxia conditions upregulate expression of CCL28 to promote recruitment of CCR10-expressing regulatory T (Treg) cells for the tumor tolerance and angiogenesis (Facciabene et al., 2011).”
BackgroundModulation of Immunity by Antiangiogenic Molecules in Cancer
Terme, M., Colussi, O., Marcheteau, E., Tanchot, C., Tartour, É., & Taïeb, J. (2012) · Clinical and Developmental Immunology · doi:10.1155/2012/492920 · Cited by 122
“Tumor-derived Treg expansion is usually attributable to four different mechanisms: preferential migration towards tumor via hypoxia which induced a special set of chemokines preferentially recruiting Treg [49], conversion of conventional T cells into Treg, proliferation of preexisting Treg, and preferential survival o…”
BackgroundThe pros and cons of chemokines in tumor immunology
Viola, A., Sarukhan, A., Bronte, V., & Molon, B. (2012) · Trends in Immunology · doi:10.1016/j.it.2012.05.007 · Cited by 131
Advancement of cancer immunotherapy using nanoparticles-based nanomedicine
Gowd, V., Ahmad, A., Tarique, M., Suhail, M., Zughaibi, T. A., Tabrez, S., & Khan, R. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.03.026 · Cited by 112
Orchestration of Angiogenesis by Immune Cells
Bruno, A., Pagani, A., Pulze, L., Albini, A., Dallaglio, K., Noonan, D. M., & Mortara, L. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00131 · Cited by 127
“Although this pro-angiogenic effect could be indirect, the depletion of Tregs in ovarian tumor-bearing-mice correlated with a strong reduction of the VEGFA at the tumor site, suggesting a relevant role of Tregs in promoting tumor angiogenesis in ovarian cancer (179).”
BackgroundJin, W., Xu, H., Zhang, S., Li, H., Wang, W., Gao, H.-L., Wu, C., Xu, J., Qi, Z.-H., Li, S., et al. (2018) · Annals of Surgical Oncology · doi:10.1245/s10434-018-6941-4 · Cited by 123
In vivo labeling reveals continuous trafficking of TCF-1+ T cells between tumor and lymphoid tissue
Li, Z., Tuong, Z. K., Dean, I., Willis, C., Gaspal, F., Fiancette, R., Idris, S., Kennedy, B. C., Ferdinand, J. R., Peñalver, A., et al. (2022) · The Journal of Experimental Medicine · doi:10.1084/jem.20210749 · Cited by 124
Li, H., Wang, M., Huang, B., Zhu, S.-W., Zhou, J.-J., Chen, D.-R., Cui, R., Zhang, M., & Sun, Z.-J. (2021) · Nature Communications · doi:10.1038/s41467-021-27485-0 · Cited by 110
The CC and CXC chemokines: major regulators of tumor progression and the tumor microenvironment
Bikfalvi, A., & Billottet, C. (2020) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00378.2019 · Cited by 123
Tumor metastasis: Mechanistic insights and therapeutic interventions
Liu, M., Yang, J., Xu, B.-S., & Zhang, X. (2021) · MedComm · doi:10.1002/mco2.100 · Cited by 136
Hypoxic Stress-Induced Tumor and Immune Plasticity, Suppression, and Impact on Tumor Heterogeneity
Terry, S., Buart, S., & Chouaïb, S. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01625 · Cited by 117
“In a setting where immunosuppression mediated by regulatory T cell (Treg) could represent one relevant mechanism for tumor immune evasion, work by Facciabene and colleagues nicely showed that tumor hypoxia promotes the recruitment of Tregs through inducing chemokine CC-chemokine ligand 28 (CCL28) expression, which, in…”
BackgroundTNFSF14: LIGHTing the Way for Effective Cancer Immunotherapy
Skeate, J. G., Otsmaa, M., Prins, R., Fernandez, D. J., Silva, D. M. D., & Kast, W. M. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00922 · Cited by 127
Hasmim, M., Noman, M. Z., Messai, Y., Bordereaux, D., Gros, G., Baud, V., & Chouaib, S. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1302140 · Cited by 109
“Although hypoxia can promote immune tolerance (13), to the best of our knowledge, this is the first demonstration that Nanog, a transcription factor known to be involved in the maintenance of stem cell–like properties, regulates the recruitment of Tregs, macrophages, and CD8 T lymphocytes in the tumor bed.”
Background
Metadata
- Authors
- Facciabene, A., Peng, X., Hagemann, I. S., Balint, K., Barchetti, A., Wang, L.-P., Gimotty, P. A., Gilks, C. B., Lal, P., Zhang, L., & Coukos, G.
- Affiliations
- University of Pennsylvania (US)
- University of British Columbia (CA)
- Corresponding author
- Coukos, George
- ORCID
- Venue
- Nature
- Published
- 2011-07
- Volume
- 475
- Issue
- 7355
- Pages
- 226-230
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2142644858
- Cited by
- 1,376
- References
- 38
- Citations by year
- 2026: 54 · 2025: 90 · 2024: 112 · 2023: 113 · 2022: 151 · 2021: 152 · 2020: 119 · 2019: 105 · 2018: 77 · 2017: 85 · 2016: 74 · 2015: 55 · 2014: 55 · 2013: 69 · 2012: 50
- FWCI
- 26.40
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- National Cancer Institute (R01CA116779, P01 CA 83638)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Keywords
- tumor hypoxia, regulatory T cells, CCL28, chemokine recruitment, tumor angiogenesis, VEGF-A, tumor immune evasion, tumor growth, chemokines
- MeSH terms
- Animals, Female, Humans, Immune Tolerance, Mice, Inbred C57BL, Neovascularization, Pathologic, Ovarian Neoplasms, Cell Hypoxia, Gene Expression Regulation, Neoplastic, Culture Media, Conditioned, Disease Progression, Chemokines, CC, Vascular Endothelial Growth Factor A, Cell Line, Tumor, T-Lymphocytes, Regulatory, Mice, Receptors, CCR10
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.